Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). AEterna Zentaris's share price for the quarter that ended in Mar. 2024 was €7.72. AEterna Zentaris's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 1.21 Mil. Therefore, AEterna Zentaris's market cap for the quarter that ended in Mar. 2024 was €9.37 Mil.
AEterna Zentaris's quarterly market cap
declined
from Sep. 2023 (€10.73 Mil) to Dec. 2023 (€8.37 Mil) but then
increased
from Dec. 2023 (€8.37 Mil) to Mar. 2024 (€9.37 Mil).
AEterna Zentaris's annual market cap
declined
from Dec. 2021 (€40.43 Mil) to Dec. 2022 (€13.40 Mil) and
declined
from Dec. 2022 (€13.40 Mil) to Dec. 2023 (€8.37 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. AEterna Zentaris's Enterprise Value for Today is €-6.29 Mil.
AEterna Zentaris Market Cap Historical Data
The historical data trend for AEterna Zentaris's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of AEterna Zentaris's Market Cap
For the Biotechnology subindustry, AEterna Zentaris's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AEterna Zentaris's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AEterna Zentaris's Market Cap distribution charts can be found below:
* The bar in red indicates where AEterna Zentaris's Market Cap falls into.
AEterna Zentaris Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
AEterna Zentaris's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AEterna Zentaris (STU:ET80) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
AEterna Zentaris Market Cap Related Terms
Thank you for viewing the detailed overview of AEterna Zentaris's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:ET80 has been successfully added to your 